Valuation: GlucoTrack, Inc.

Market Cap 2.17M 1.86M 1.74M 1.6M 2.99M 208M 3.03M 20.59M 8.03M 105M 8.16M 7.99M 346M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -1.76M -1.51M -1.41M -1.29M -2.43M -169M -2.46M -16.69M -6.51M -84.71M -6.62M -6.47M -280M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
88.48%
Yield 2024 *
-
Yield 2025 -
1 day+1.70%
1 week-5.44%
Current month-27.17%
1 month+13.57%
3 months-30.52%
6 months-77.29%
Current year-91.02%
1 week 0.31
Extreme 0.3067
0.4
1 month 0.25
Extreme 0.25
0.9
Current year 0.25
Extreme 0.25
4.24
1 year 0.25
Extreme 0.25
14.14
3 years 0.25
Extreme 0.25
5,939.99
5 years 0.25
Extreme 0.25
38,999.92
10 years 0.25
Extreme 0.25
468,000.47
Manager TitleAgeSince
Chief Executive Officer 55 2026-07-13
Director of Finance/CFO 66 2025-01-27
Chief Operating Officer - 2025-01-31
Director TitleAgeSince
Director/Board Member 59 2024-08-26
Director/Board Member 56 2023-08-24
Chairman 64 2024-02-12
Date Insider Type Main position Quantity % Market Cap.
3/26/25 Free

Director

4,490 0.0431%
3/25/25 Free

Director

8,747 0.0840%
3/25/25 Free

Director

5,473 0.0526%
Change 5-day change 1-year change 3-year change Capi.($)
+1.70%-5.44%-93.72%-99.98% 2.17M
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average +0.57%+3.45%+63.45%+101.17% 27.65B
Weighted average by Cap. +0.49%+4.72%+99.57%+146.29%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.36M -18.11M -16.58M -31.11M -2.16B -31.53M -214M -83.45M -1.09B -84.85M -83M -3.59B -19.39M -16.61M -15.54M -14.22M -26.7M -1.86B -27.05M -184M -71.6M -932M -72.8M -71.22M -3.08B
Net Debt -5.35M -4.58M -4.29M -3.93M -7.37M -512M -7.46M -50.66M -19.76M -257M -20.09M -19.65M -851M -3.94M -3.37M -3.16M -2.89M -5.42M -377M -5.49M -37.28M -14.54M -189M -14.78M -14.46M -626M
Logo GlucoTrack, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
26-08-21 US$0.3474 +1.70% 697,604
26-08-20 US$0.3416 -2.06% 532,409
26-08-19 US$0.3488 +1.10% 428,988
26-08-18 US$0.3450 +0.88% 1,466,226
26-08-17 US$0.3420 -6.91% 23,845,428
  1. Stock Market
  2. Stocks
  3. GCTK Stock